Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 113

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 113
---
is Master Fund. The principal business address of Iroquois        
 Master Fund Ltd. is c/o Iroquois Capital Management, LLC, 2 Overhill Road, Suite 400, Scarsdale, NY 10583.                                    |

| 62 |

| (12) | The selling shareholder holds Replacement Warrants issued by us                                                                                
 which entitle the selling shareholder to purchase an aggregate of 28,500,000 Ordinary Shares                                                   
 (in the form of Depositary Shares) which we are registering hereby. The warrants are subject to a beneficial ownership limitation of 4.99%,    
 which does not permit the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder and        
 its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts and       
 percentages in the table do not give effect to the 4.99% beneficial ownership limitation, if applicable. Kingsbrook Partners LP, or Kingsbrook 
 Partners, is the investment manager of Kingsbrook Opportunities Master Fund LP, or Kingsbrook Opportunities, and consequently has voting       
 control and investment discretion over securities held by Kingsbrook Opportunities. Kingsbrook Opportunities GP LLC, or Opportunities          
 GP, is the general partner of Kingsbrook Opportunities and may be considered the beneficial owner of any securities deemed to be beneficially  
 owned by Kingsbrook Opportunities. KB GP LLC, or GP LLC, is the general partner of Kingsbrook Partners and may be considered the beneficial    
 owner of any securities deemed to be beneficially owned by Kingsbrook Partners. Ari J. Storch, Adam J. Chill and Scott M. Wallace are          
 the sole managing members of Opportunities GP and GP LLC and as a result may be considered beneficial owners of any securities deemed          
 beneficially owned by Opportunities GP and GP LLC. Each of Kingsbrook Partners, Opportunities GP, GP LLC and Messrs. Storch, Chill and         
 Wallace disclaim beneficial ownership of these securities. The principal business address of Kingsbrook Opportunities is c/o Kingsbrook        
 Partners, 689 Fifth Avenue, 12th Floor, New York, New York 10022.                                                                              |

| (13) | The selling shareholder (i) warrants issued by us in                                                                                         
 a prior transaction which entitle the selling shareholder to purchase an aggregate of 140,820,000 Ordinary Shares (in the form of Depositary 
 Shares), and (iii) Series H Warrants issued by us which entitle the selling shareholder to purchase                                          
 an aggregate of 183